FDA Starts Review of Biogenís Therapy for Hemophilia B

by Kathy Jones on  March 5, 2013 at 9:06 PM Drug News
RSS Email Print This Page Comment
The US Food and Drug Administration is currently reviewing Biogen Idec's application for a fusion protein therapy designed to treat hemophilia B, the company said.
 FDA Starts Review of Biogenís Therapy for Hemophilia B
FDA Starts Review of Biogenís Therapy for Hemophilia B
Advertisement

The company revealed that its drug, rFIXFc, has been designed to last longer than currently available drugs and allows patients to endure fewer treatments.

Advertisement
The FDA will be conducting a 10-month review of the drug and is expected to reach a decision in January next year.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Genetic Counseling Reiki and Pranic Healing von Willebrand Disease Bleeding Disorders Hemophilia 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive